NEW YORK and NEW ORLEANS, Oct. 9, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgm-bbnx/

Beta Bionics investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaq-bbnx/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects.

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) the Company's sole commercialized device, the iLet Bionic Pancreas insulin pump ("iLet"), employed an aggressive automated dosing algorithm that malfunctioned and delivered dangerously high levels of insulin, causing hypoglycemic events, including hundreds of life-threatening events requiring medical intervention and hospitalization; (ii) the Company had received thousands of related customer complaints that it failed to investigate or timely report to the U.S. Food and Drug Administration ("FDA"); (iii) the FDA Form 483 issued to the Company in June 2025 identified more than 18,000 unreported complaints and was not, as Defendants represented, limited to a minor difference in interpretation of which complaints were reportable; (iv) the Company had failed to implement meaningful corrective actions in response to the Form 483, resulting in an FDA warning letter concerning the Company's quality management system, medical device reporting, and corrections and removals; and (v) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

The case is Holtzman v. Beta Bionics, Inc. et al., 26-cv-09999.

WHAT TO DO? If you invested in Beta Bionics and suffered a loss during the relevant time frame, you have until November 3, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3666

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

Share this article

NEW YORK and NEW ORLEANS, Oct. 9, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Duolingo, Inc. (NasdaqGS: DUOL) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Pennsylvania.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-duol/

Duolingo investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-duol/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects.

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) Duolingo was deliberately adding friction to the user experience, through sharply increased ad volume, upselling of subscription tiers, and declining product quality, which Defendants knew would drive users away from the app and ultimately slow Daily Active User ("DAU") growth; (ii) Duolingo's extensive A/B testing showed Defendants that added friction in the free user experience was hurting DAU growth; (iii) Duolingo's rapidly produced AI content was degrading its product offerings, harming the user experience and user trends, and putting the sustainability of Duolingo's financial performance at risk; and (iv) rather than fueling sustained growth and strong user momentum through content and "product improvements" that "get improved retention," Duolingo's monetization push and lower-quality AI content were, as its ongoing A/B testing revealed, eroding both the product experience and the value of its subscription tiers.

The case is City of Dearborn Heights Act 345 Police & Fire Retirement System v. Duolingo, Inc., No. 26-cv-02199.

WHAT TO DO? If you invested in Duolingo and suffered a loss during the relevant time frame, you have until December 7, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3666

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

Share this article

NEW YORK and NEW ORLEANS, Oct. 9, 2026 /PRNewswire/ -- - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of Hims as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-hims/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 2, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Hims & Hers Health and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced that it had filed a lawsuit against the Company "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The FTC further alleged that the Company fails to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'"

On this news, the price of Hims & Hers Health shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, on unusually heavy trading volume.

The case is Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3666

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

Share this article

NEW ORLEANS, Oct. 9, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS).

On August 2, 2023, the Company announced its financial results for the quarter ended June 30, 2023, disclosing that it was revising its diluted earnings-per-share ("EPS") guidance range to $6.53 to $6.75 from $6.90 to $7.12 and that operating income "decreased $1.4 billion, or 30.7%, in the three months ended June 30, 2023 compared to the prior year primarily due to declines in the Health Care Benefits segment[.]"

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF's investigation is focusing on whether CVS' officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of CVS shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cvs/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3606

1100 Poydras St., Suite 3200

New Orleans, LA 70163

SOURCE Kahn Swick & Foti, LLC

Share this article

NEW YORK and NEW ORLEANS, Oct. 9, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has continued its investigation into Microvast Holdings, Inc. (NasdaqCM: MVST).

On November 21, 2023, J Capital Research published a report entitled "MVST: Empty Facilities and a Grant Loss That Was Probably Hidden: Another China Hustle" alleging that the Company knew that a proposed $200 million U.S. Department of Energy Grant to help fund a proposed polyaramid separator production facility had been rescinded for months prior to a May 2023 Reuters report, but failed to inform investors. The report further alleged that "the majority of MVST's sales may be fake"; that "Chinese customers account for 57% of revenue in 2023" but drone footage showed the Company's Chinese factory "shows almost no activity"; that the Company "has disappeared from Chinese procurement lists" and "local competitors say the company is not making discernible sales," and that the Company's reported backlog was "dubious."

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information in violation of federal securities laws. The court presiding over that case has denied the Company's motion to dismiss in part, allowing the case to move forward.

KSF's investigation is focusing on whether Microvast's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Microvast shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqcm-mvst/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-833-538-3606

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

Share this article

SAN DIEGO, Oct. 9, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of The Ensign Group, Inc. (NASDAQ: ENSG) publicly traded securities between February 10, 2022 and June 18, 2026, inclusive (the "Class Period"), have until December 7, 2026 to seek appointment as lead plaintiff of the Ensign Group class action lawsuit. Captioned Perusek v. The Ensign Group, Inc., No. 26-cv-02963 (C.D. Cal.), the Ensign Group class action lawsuit charges Ensign Group and certain of Ensign Group's top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Ensign Group class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-the-ensign-group-inc-class-action-lawsuit-ensg.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Ensign Group provides skilled nursing, senior living, and rehabilitative services.

The Ensign Group class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Ensign Group's business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (ii) Ensign Group's abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (iii) Ensign Group uses self-reporting measures as a way to cover up that it systematically neglects patients; (iv) Ensign Group defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (v) Ensign Group falsifies the number of hours that Certified Nursing Assistants spend with residents; (vi) Ensign Group engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; and (vii) Ensign Group materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model.

The Ensign Group class action lawsuit further alleges that on June 8, 2026, Hunterbrook Media published a report entitled "Ensign: The Nursing Home Empire Built on Fatal Neglect," which alleged, among other things, that "Ensign's business model relies on delivering inadequate care to patients while gaming data on quality . . . . Patients are dying." On this news, the price of Ensign Group stock fell more than 8%.

Then, on June 11, 2026, Muddy Waters Research published a report entitled "Ensign: Deceiving the Government at Estimated ~20% of Facilities." On this news, the price of Ensign Group stock fell further.

Finally, on June 18, 2026, Hunterbrook Media issued a follow up report entitled "New: Patients Hungry in Ensign Facilities." The article stated that Ensign Group caregivers and residents had reached out to Hunterbrook Media to add "new, firsthand evidence of resident hunger, payroll falsification, understaffing, and staff licensing issues." On this news, the price of Ensign Group stock fell further.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Ensign Group publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Ensign Group class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Ensign Group class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Ensign Group class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Ensign Group class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP

Ken Dolitsky

Michael Albert

655 W. Broadway, Suite 1900, San Diego, CA 92101

800/851-7783

[email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

Share this article

NEW YORK, Oct. 9, 2026 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Priority Technology Holdings, Inc. ("PRTH" or the "Company") (NASDAQ: PRTH) stock prior to September 18, 2026.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of PRTH by its largest stockholder, Chairman, and CEO, Thomas C. Priore. As a result of the merger, PRTH stockholders are expected to receive only $8.05 per share in cash in exchange for each share of common stock.

To receive more information, go to:

https://zlk.com/cases/priority-technology-investigation-prth

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.

The PRTH merger investigation concerns whether PRTH's Board of Directors have harmed stockholders by failing to maximize the Company's merger price and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits, and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE Levi & Korsinsky, LLP

Share this article

Two Wall Street downgrades followed CMS's 3.5-star 2027 rating for the Alignment Healthcare contract covering more than 75% of its health-plan members. ALHC opened to a roughly 20% decline, and an investigation into potential securities law violations is underway.

NEW YORK, Oct. 9, 2026 /PRNewswire/ -- Alignment Healthcare, Inc. (NASDAQ: ALHC) shares opened down roughly 20% on October 9, 2026, after the Centers for Medicare & Medicaid Services (CMS) released its 2027 Medicare Advantage Star Ratings, lowering the Company's California H3815 HMO contract to 3.5 stars from 4.0 stars. If you held ALHC shares when the ratings landed and lost money, you may have legal rights. Investors who suffered losses are encouraged to submit their ALHC loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

Alignment's October 8 announcement reported that six of its seven eligible contracts earned four stars or higher. The seventh contract, H3815, covers more than 75% of its health-plan members and slipped from 4.0 to 3.5 stars. Reportedly, following the news, Bank of America and William Blair both cut their price targets and downgraded to neutral / market perform positions, with the latter cutting their price target by more than 60%.

Previously, during the Company's most recent earnings call on July 30, 2026, CEO John E. Kao indicated that, despite the "shaky" "regulatory and legal footing" surrounding stars, he "felt good about [Alignment's] position." Additionally, Alignment's share price had previously faltered on September 15, 2026, following comments at a Baird conference where CEO Kao reportedly refused to comment on the pending star rating decisions: "I cannot talk about it at all … we do not want to be the one poking the bear."

Shareholders who lost money as ALHC repriced can share their trading losses with our team or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the ALHC Investigation

Q: How much did ALHC stock drop?A: Shares fell from a closing price of $8.71 on October 8, 2026, to an opening price of just $6.95 the following morning, an overnight decline of roughly $1.76 per share, or about 20%. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: When did Alignment Healthcare allegedly mislead investors?A: The investigation concerns statements made before the October 8, 2026 disclosure of the 2027 Star Ratings. Those statements allegedly caused investors to purchase ALHC securities at inflated prices.

Q: Who is eligible to participate in the ALHC investigation?A: Investors who purchased ALHC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do ALHC investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my ALHC shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ALHC and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis. Any attorneys' fees and expenses are subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Share this article

NEW YORK, Oct. 9, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026 in the securities class action first filed by the Firm.

So what: If you purchased Ensign securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Ensign class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Ensign's business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (2) Ensign's abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (3) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (4) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (5) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (6) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; (7) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and (8) as a result, defendants' statements about Ensign's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ensign class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY  10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected] 

www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

NEW YORK, Oct. 9, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Sprout Social, Inc. (NASDAQ: SPT).

If you currently own shares of Sprout Social stock, please visit the firm's website at https://rosenlegal.com/cases/sprout-social-inc/join for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected].

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY  10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article